# Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

> **NCT01236638** · PHASE2 · COMPLETED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 120 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Momelotinib

## Key facts

- **NCT ID:** NCT01236638
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01236638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01236638, "Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01236638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*